到 2028 年的 3D 生物打印市场预测 - 按组件、材料、应用、最终用户和地区进行的全球分析

根据Stratistics MRC，2022年全球3D生物打印市场规模将达到20.5亿美元，预计2028年将达到55亿美元，预测期内增长17.9%。预计以 100% 的复合年增长率增长。

在称为 3D 生物打印的过程中，活细胞与生物材料相结合，以实现细胞和生物墨水的精确逐层沉积。 它的特点是在 3D 环境中保持细胞活力的分层结构特性，并且可以创建多方面和復杂的组织。 这项技术的最终结果可能是自然模仿构成人体的组织和结构的生物学和功能特性的产品。

根据Interesting Engineering的一篇文章，悉尼新南威尔士大学的工程师们成功开发出一种3D生物打印设备“F3DB”，可以直接将多层生物材料转移到组织和内臟表面。据说已经公布了。

市场动态

驱动程序

扩大 3D 生物打印在製药和化妆品行业的应用

製药和化妆品行业越来越多地使用 3D 生物打印技术，对市场产生了巨大影响。 3D 生物打印允许创建传统技术无法实现的复杂 3D 结构。 这使得复杂的药物配方和分子、人造皮肤和毛囊等化妆品的生产成为可能。 製药和化妆品行业对 3D 生物打印产品的需求不断增长，这是市场的主要驱动力。

约束

缺乏合格的专业人员

主要的市场製约因素之一是市场上缺乏合格的专业人员。 随着对尖端 3D 生物打印技术的需求不断增长，合格人员的短缺阻碍了市场的扩张。 3D生物打印设备的操作和维护需要熟练的专业人员。 合格专业人员的短缺削弱了 3D 生物打印技术发挥其全部潜力的潜力。 僱用和培训合格人员的高成本也是抑制市场扩张的一个因素。

机会

政府财政支持

世界各国政府正在合作资助涉及 3D 生物打印的研发项目。 例如，五所研究型大学最初从美国食品和药物管理局 (FDA) 获得了总额为 25 亿美元的拨款，用于 3D 生物打印的研发。 资助方包括哈佛大学、卡内基梅隆大学、罗格斯大学、麻省理工学院和佐治亚理工学院。 这是预测期内推动 3D 生物打印市场收入增长的关键因素。

威胁

缺乏监管标准

3D 生物打印监管标准的缺乏预计会阻碍市场收入的增长。 例如，负责监督生物製品营销的 FDA 生物製品评估与研究中心 (CBER) 既未批准 3D 打印生物製品，也未就其使用提出明确建议。 然而，监管标准的缺乏制约了生物3D打印市场的发展。

COVID-19 的影响：

由于供应链中断、对治疗药物和材料的需求增加以及製造技术的进步，COVID-19 大流行显着加速了这些领域的技术发展。 随着受 COVID-19 影响的人数增加，对器官和组织生产的需求也在增加。 许多 3D 生物打印市场参与者正在开发 COVID-19 疫苗，以减轻该流行病的影响。 对药品的需求正在增长，行业参与者的数量也在增长。 此外，3D 打印社区支持开发必要的医院设备以应对 COVID-19 的情况。

预计 3D 生物打印机细分市场将成为预测期内最大的细分市场

由于药片广泛用于治疗各种慢性病，预计 3D 生物打印机部分在预测期内将占据最大的市场份额。 对药品的需求不断增长以及生物製药在该技术中的有效应用是推动该领域发展的其他因素。 随着行业参与者数量的增加，对药品的需求也在增加。 全世界有数百万人出于医疗原因定期服用药片和胶囊。 因此，该细分市场有望在预测期内实现盈利增长。

预计医疗行业在预测期内的复合年增长率最高。

医疗行业有望在预测期内实现良好增长。 由于药片广泛用于治疗各种慢性疾病，3D 生物打印市场正在增长。 此外，对药品不断增长的需求以及该技术对生物製药的有效利用也推动了这一领域的发展。

市场份额最高的地区

在预测期内，预计北美将主导全球市场。 北美目标人口数量的增加是该地区占据主导地位的原因。 由于该地区存在主要参与者和先进的医疗保健基础设施，预计北美 3D 生物打印市场将有增长机会。 预计区域参与者增加对各种研发计划的投资也将推动未来几年的市场增长。

复合年增长率最高的地区：

亚太地区预计在预测期内的复合年增长率最高，原因是其老年人口众多以及政府为加强医疗保健行业而采取的强有力举措和政策。 日本政府预测，再生医学产业到2030年将增长到1万亿日元的规模。 由于 COVID-19 案件数量的增加和政府研发支出的增加，日本和中国占了大部分收入。 此外，COVID-19死亡率上升和器官捐献者短缺预计将推动区域市场的扩张。

主要发展：

2022 年 6 月，Humabiologics 和 REGEMAT 3D 将满足欧洲药物检测和生物打印市场不断增长的需求，并为更广泛的生命科学客户群提供服务，包括学术机构及其行业合作伙伴已宣布一项非独家经销协议。

2022 年 5 月，Organovo Holdings 宣布成功开发出第一个以克罗恩病的发现和验证为目标的炎症性肠病 (IBD) 模型。 根据内部数据，该公司认为其 IBD 模型可以重新定义克罗恩病患者与未患克罗恩病患者不同的重要生物学方面。

2021 年 4 月，Aspect Biosystems, Inc. 宣布与糖尿病研究和宣传领域的先驱 JDRF 建立合作伙伴关係。 通过此次合作，两家公司将专注于开发可治疗 1 型糖尿病的 3D 生物打印组织。

我们的报告提供了什么

• 区域和国家/地区细分市场份额评估
• 向新进入者提出战略建议
• 2020、2021、2022、2025 和 2028 年的综合市场数据
• 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会、建议）。
• 根据市场预测在关键业务领域提出战略建议
• 竞争格局映射关键共同趋势。
• 公司简介，包括详细的战略、财务状况和近期发展
• 映射最新技术进步的供应链趋势

免费定制优惠：

购买此报告的客户将获得以下免费定制选项之一：

• 公司简介
  • 其他市场参与者的综合概况（最多 3 家公司）
  • 主要参与者的 SWOT 分析（最多 3 家公司）
• 区域细分
  • 根据客户的要求对主要国家/地区的市场估计/预测/复合年增长率（注意：基于可行性检查）。
• 竞争基准
  • 根据产品组合、区域影响力和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

• 概览
• 利益相关者
• 调查范围
• 调查方法
  • 数据挖掘
  • 数据分析
  • 数据验证
  • 研究方法
• 调查来源
  • 主要研究来源
  • 二级研究来源
  • 假设

第三章市场趋势分析

• 司机
• 约束因素
• 机会
• 威胁
• 应用分析
• 最终用户分析
• 新兴市场
• COVID-19 的影响

第 4 章波特五力分析

• 供应商的议价能力
• 买家的议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第 5 章全球 3D 生物打印市场：按组件分类

• 3D 生物打印机
  • 微挤压生物打印
  • 喷墨 3D 生物打印
  • 注射器/挤压生物打印
  • 激光辅助生物打印
  • 基于立体光刻的生物打印
  • 磁性 3D 生物打印
  • 其他 3D 生物打印机
• 生物墨水
  • 自然
  • 混合型
  • 综合

第 6 章全球 3D 生物打印市场：按材料分类

• 生物材料
  • 活细胞
  • 水凝胶
  • 细胞外基质
  • 其他生物材料

第 7 章全球 3D 生物打印市场：按应用

• 医学
  • 组织和器官的产生
  • 药丸
  • 假肢和植入物
  • 其他药物
• 药物测试和调查
• 临床移植
• 食品检验
• 再生医学
• 消费者/个人产品测试
• 癌症研究
• 生物传感器
• 其他用途

第 8 章全球 3D 生物打印市场：按最终用户分类

• 研究和学术机构
• 生物製药公司
• 医院

第 9 章全球 3D 生物打印市场：按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 意大利
  • 法国
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 新西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 其他南美洲
• 中东和非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 卡塔尔
  • 南非
  • 其他中东和非洲地区

第10章主要发展

• 合同、伙伴关係、协作和合资企业
• 收购与合併
• 新产品发布
• 业务扩展
• 其他关键策略

第11章公司简介

• 3D Bioprinting Solutions
• 3D Systems Corporation
• Advanced Solutions Life Sciences, LLC
• Allevi Inc.
• Arcam AB
• Aspect Biosystems Ltd.
• Bico group ab
• Bio3D Technologies Pte. Ltd.
• Cellink
• Collplant Biotechnologies Ltd.
• Cyfuse Biomedical K.K.
• Electro Optical Systems
• Envision TEC GmbH
• Foldink Life Science Technologies
• Formlabs, Inc.
• GE Healthcare
• GeSIM GmbH
• Inventia Life Science PTY LTD
• Optomec Inc.
• Organovo Holdings Inc.
• Pandorum Technologies pvt. ltd.
• Poietis
• Precise Bio
• REGEMAT 3D
• Regenovo Biotechnology Co. Ltd.
• Renishaw plc.
• Revotek co., ltd.
• Rokit Healthcare, inc.
• Stratasys Ltd

According to Stratistics MRC, the Global 3D Bioprinting Market is accounted for $2.05 billion in 2022 and is expected to reach $5.50 billion by 2028 growing at a CAGR of 17.9% during the forecast period. Live cells are combined with biomaterials in a process called 3D bioprinting that enables precise layer-by-layer deposition of the cells or bio-ink. This is distinguished by hierarchical structural characteristics that preserve cellular viability in 3D environments to produce multifaceted and complex tissues. The end results of this technique can be products that mimic the biological and functional characteristics of the tissues and structures that make up the human body naturally.

According to an article by Interesting Engineering, engineers at the University of New South Wales, Sydney, published a paper wherein they successfully developed a 3D bio-printed device, F3DB, that can directly transfer multi-layered biomaterials on the surface of the tissues and internal organs.

Market Dynamics:

Driver:

Increasing use of 3D bioprinting in the pharmaceutical and cosmetic industries

The market has been significantly influenced by the growing use of 3D bioprinting in the pharmaceutical and cosmetic industries. Complex 3D structures can be created using 3D bioprinting, which is not possible with conventional techniques. This has made it possible to produce intricate drug formulations and molecules, as well as cosmetic products like synthetic skin, hair follicles, and other tissues. The pharmaceutical and cosmetic industries' rising need for 3D bioprinted products has been a key market driver.

Restraint:

Lack of qualified professionals

One of the main market constraints is the lack of qualified professionals in the market. The market's expansion has been hampered by a lack of qualified professionals as demand for cutting-edge 3D bioprinting technology rises. To operate and maintain 3D bioprinting equipment, skilled professionals are required. The likelihood that 3D bioprinting technology will realize its full potential has been reduced by a lack of qualified professionals. The high cost of hiring and training qualified professionals is another factor impeding market expansion.

Opportunity:

Funding from the governments

Governments from various nations are working together to fund research and development projects involving 3D bioprinting. For instance, the first five research universities received a grant from the US Food and Drug Administration (FDA) for three dimensional bioprinting research and development totaling USD 2.5 billion. The grant recipients included Harvard University, Carnegie Mellon University, Rutgers University, Massachusetts Institute of Technology, and Georgia Institute of Technology. This is a significant factor that is predicted to boost the three-dimensional bioprinting market's revenue growth over the forecast period.

Threat:

Absence of regulatory standards

The absence of regulatory standards for 3D bioprinting is anticipated to impede market revenue growth. For instance, the FDA's Center for Biologics Evaluation and Research (CBER), which oversees the sale of biological commodities, has neither approved any 3D-printed biological products nor made any explicit recommendations regarding their use. The absence of regulatory standards, however, places a constraint on the growth of the 3D bioprinting market.

COVID-19 Impact:

Due to disrupted supply chains, increased demand for treatments and materials, and manufacturing technology advancements, the COVID-19 pandemic significantly accelerated these fields' technological development. There is a growing need for organ and tissue production as the number of COVID-19 illness cases rises. The COVID-19 vaccine is being developed by a number of 3D bioprinting market participants to mitigate the effects of the outbreak. As well as the number of industry participants, the demand for pharmaceutical products is rising. Moreover, the 3D printing community responded to the COVID-19 situation by supporting the development of essential hospital equipment.

The 3D bioprinters segment is expected to be the largest during the forecast period

Due to the widespread use of pharmaceutical pills to treat a variety of chronic conditions, the 3D bioprinters segment is expected to hold the largest market share during the forecast period. The growing demand for pharmaceuticals and the effective application of bio-drugs in this technology are other factors driving the segment. Along with an increase in industry participants, the demand for pharmaceutical products is also rising. Millions of people regularly take pills and capsules for medical reasons all over the world. As a result, it is anticipated that this market segment will expand profitably over the course of the forecast period.

The medical segment is expected to have the highest CAGR during the forecast period

The medical segment is expected to witness lucrative growth during the forecast period. The market for 3D bioprinting is expanding due to the widespread use of pharmaceutical pills to treat a variety of chronic diseases. Additionally, the segment is also being driven by the expanding demand for medicines and the efficient use of bio-drugs in this technology.

Region with largest share:

Over the forecast period, North America is anticipated to dominate the global market. The increased target population count in North America is blamed for the area's dominance. The North American 3D bioprinting market is expected to experience growth opportunities due to the presence of key players and the region's sophisticated healthcare infrastructure. In the upcoming years, it is anticipated that increased regional players' investments in a variety of R&D initiatives will also help the market grow.

Region with highest CAGR:

Asia Pacific is estimated to witness the highest CAGR over the projection timeframe, owing to a senior population and favorable government initiatives and policies to strengthen the healthcare sector in this region. By 2030, the Japanese government projects that the regenerative medicine industry will have grown to 1 trillion yen. Due to the rise in COVID-19 cases and government R&D spending, Japan and China accounted for the lion's share of the revenue. Furthermore, COVID-19's increased mortality rate and the scarcity of organ donors are expected to fuel the expansion of the regional market.

Key players in the market:

Some of the key players profiled in the 3D Bioprinting Market include: 3D Bioprinting Solutions, 3D Systems Corporation, Advanced Solutions Life Sciences, LLC, Allevi Inc., Arcam AB, Aspect Biosystems Ltd., Bico group ab, Bio3D Technologies Pte. Ltd., Cellink, Collplant Biotechnologies Ltd., Cyfuse Biomedical K.K., Electro Optical Systems, Envision TEC GmbH, Foldink Life Science Technologies, Formlabs, Inc., GE Healthcare, GeSIM GmbH, Inventia Life Science PTY LTD, Optomec Inc., Organovo Holdings Inc., Pandorum Technologies pvt. ltd., Poietis, Precise Bio, REGEMAT 3D, Regenovo Biotechnology Co. Ltd., Renishaw plc., Revotek co., ltd., Rokit Healthcare, inc. and Stratasys Ltd.

Key Developments:

In June 2022, Humabiologics and REGEMAT 3D announced a non-exclusive distribution agreement in order to respond to the increasing demand and serve a broader life science customer base of academic institutes and its industry partners in the European drug testing and bioprinting market.

In May 2022, Organovo Holdings announced it had successfully advanced its first Inflammatory Bowel Disease (IBD) model to target the discovery and validation of Crohn's Disease. Based on the internal data, the company believes its IBD model can correctly demonstrate important aspects of Crohn's patient biology that differ from a non-diseased person.

In April 2021, Aspect Biosystems Ltd announced a partnership with JDRF, a pioneer in diabetes research and advocacy. Through the partnership, the companies will focus on developing 3D bio-printed tissue that is capable of treating type 1 diabetes.

Components Covered:

• 3D Bioprinters
• Bioinks

Materials Covered:

• Biomaterials

Applications Covered:

• Medical
• Drug Testing & Research
• Clinical Transplantation
• Food Testing
• Regenerative Medicine
• Consumer/Personal Product Testing
• Cancer Research
• Biosensors
• Other Applications

End Users Covered:

• Research Organizations & Academic Institutes
• Biopharmaceutical Companies
• Hospitals

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global 3D Bioprinting Market, By Component

• 5.1 Introduction
• 5.2 3D Bioprinters
  • 5.2.1 Microextrusion Bioprinting
  • 5.2.2 Inkjet 3D Bioprinting
  • 5.2.3 Syringe/extrusion Bioprinting
  • 5.2.4 Laser-Assisted Bioprinting
  • 5.2.5 Stereolithography-Based Bioprinting
  • 5.2.6 Magnetic 3D bioprinting
  • 5.2.7 Other 3D Bioprinters
• 5.3 Bioinks
  • 5.3.1 Natural
  • 5.3.2 Hybrid
  • 5.3.3 Synthetic

6 Global 3D Bioprinting Market, By Material

• 6.1 Introduction
• 6.2 Biomaterials
  • 6.2.1 Living Cells
  • 6.2.2 Hydrogels
  • 6.2.3 Extracellular Matrices
  • 6.2.4 Other Biomaterials

7 Global 3D Bioprinting Market, By Application

• 7.1 Introduction
• 7.2 Medical
  • 7.2.1 Tissue And Organ Generation
  • 7.2.2 Medical Pills
  • 7.2.3 Prosthetics And Implants
  • 7.2.4 Other Medicals
• 7.3 Drug Testing & Research
• 7.4 Clinical Transplantation
• 7.5 Food Testing
• 7.6 Regenerative Medicine
• 7.7 Consumer/Personal Product Testing
• 7.8 Cancer Research
• 7.9 Biosensors
• 7.10 Other Applications

8 Global 3D Bioprinting Market, By End User

• 8.1 Introduction
• 8.2 Research Organizations & Academic Institutes
• 8.3 Biopharmaceutical Companies
• 8.4 Hospitals

9 Global 3D Bioprinting Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 3D Bioprinting Solutions
• 11.2 3D Systems Corporation
• 11.3 Advanced Solutions Life Sciences, LLC
• 11.4 Allevi Inc.
• 11.5 Arcam AB
• 11.6 Aspect Biosystems Ltd.
• 11.7 Bico group ab
• 11.8 Bio3D Technologies Pte. Ltd.
• 11.9 Cellink
• 11.10 Collplant Biotechnologies Ltd.
• 11.11 Cyfuse Biomedical K.K.
• 11.12 Electro Optical Systems
• 11.13 Envision TEC GmbH
• 11.14 Foldink Life Science Technologies
• 11.15 Formlabs, Inc.
• 11.16 GE Healthcare
• 11.17 GeSIM GmbH
• 11.18 Inventia Life Science PTY LTD
• 11.19 Optomec Inc.
• 11.20 Organovo Holdings Inc.
• 11.21 Pandorum Technologies pvt. ltd.
• 11.22 Poietis
• 11.23 Precise Bio
• 11.24 REGEMAT 3D
• 11.25 Regenovo Biotechnology Co. Ltd.
• 11.26 Renishaw plc.
• 11.27 Revotek co., ltd.
• 11.28 Rokit Healthcare, inc.
• 11.29 Stratasys Ltd

List of Tables

• Table 1 Global 3D Bioprinting Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global 3D Bioprinting Market Outlook, By Component (2020-2028) ($MN)
• Table 3 Global 3D Bioprinting Market Outlook, By 3D Bioprinters (2020-2028) ($MN)
• Table 4 Global 3D Bioprinting Market Outlook, By Microextrusion Bioprinting (2020-2028) ($MN)
• Table 5 Global 3D Bioprinting Market Outlook, By Inkjet 3D Bioprinting (2020-2028) ($MN)
• Table 6 Global 3D Bioprinting Market Outlook, By Syringe/extrusion Bioprinting (2020-2028) ($MN)
• Table 7 Global 3D Bioprinting Market Outlook, By Laser-Assisted Bioprinting (2020-2028) ($MN)
• Table 8 Global 3D Bioprinting Market Outlook, By Stereolithography-Based Bioprinting (2020-2028) ($MN)
• Table 9 Global 3D Bioprinting Market Outlook, By Magnetic 3D bioprinting (2020-2028) ($MN)
• Table 10 Global 3D Bioprinting Market Outlook, By Other 3D Bioprinters (2020-2028) ($MN)
• Table 11 Global 3D Bioprinting Market Outlook, By Bioinks (2020-2028) ($MN)
• Table 12 Global 3D Bioprinting Market Outlook, By Natural (2020-2028) ($MN)
• Table 13 Global 3D Bioprinting Market Outlook, By Hybrid (2020-2028) ($MN)
• Table 14 Global 3D Bioprinting Market Outlook, By Synthetic (2020-2028) ($MN)
• Table 15 Global 3D Bioprinting Market Outlook, By Material (2020-2028) ($MN)
• Table 16 Global 3D Bioprinting Market Outlook, By Biomaterials (2020-2028) ($MN)
• Table 17 Global 3D Bioprinting Market Outlook, By Living Cells (2020-2028) ($MN)
• Table 18 Global 3D Bioprinting Market Outlook, By Hydrogels (2020-2028) ($MN)
• Table 19 Global 3D Bioprinting Market Outlook, By Extracellular Matrices (2020-2028) ($MN)
• Table 20 Global 3D Bioprinting Market Outlook, By Other Biomaterials (2020-2028) ($MN)
• Table 21 Global 3D Bioprinting Market Outlook, By Application (2020-2028) ($MN)
• Table 22 Global 3D Bioprinting Market Outlook, By Medical (2020-2028) ($MN)
• Table 23 Global 3D Bioprinting Market Outlook, By Tissue And Organ Generation (2020-2028) ($MN)
• Table 24 Global 3D Bioprinting Market Outlook, By Medical Pills (2020-2028) ($MN)
• Table 25 Global 3D Bioprinting Market Outlook, By Prosthetics And Implants (2020-2028) ($MN)
• Table 26 Global 3D Bioprinting Market Outlook, By Other Medicals (2020-2028) ($MN)
• Table 27 Global 3D Bioprinting Market Outlook, By Drug Testing & Research (2020-2028) ($MN)
• Table 28 Global 3D Bioprinting Market Outlook, By Clinical Transplantation (2020-2028) ($MN)
• Table 29 Global 3D Bioprinting Market Outlook, By Food Testing (2020-2028) ($MN)
• Table 30 Global 3D Bioprinting Market Outlook, By Regenerative Medicine (2020-2028) ($MN)
• Table 31 Global 3D Bioprinting Market Outlook, By Consumer/Personal Product Testing (2020-2028) ($MN)
• Table 32 Global 3D Bioprinting Market Outlook, By Cancer Research (2020-2028) ($MN)
• Table 33 Global 3D Bioprinting Market Outlook, By Biosensors (2020-2028) ($MN)
• Table 34 Global 3D Bioprinting Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 35 Global 3D Bioprinting Market Outlook, By End User (2020-2028) ($MN)
• Table 36 Global 3D Bioprinting Market Outlook, By Research Organizations & Academic Institutes (2020-2028) ($MN)
• Table 37 Global 3D Bioprinting Market Outlook, By Biopharmaceutical Companies (2020-2028) ($MN)
• Table 38 Global 3D Bioprinting Market Outlook, By Hospitals (2020-2028) ($MN)

Note: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa Regions are also represented in the same manner as above.